Factors Associated With Sub - Targeted Therapeutic Dose Of Renin - Angiotensin Blockage Among Chronic Heart Failure With Reduced Ejection Fraction Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06382571

Enrollment

396

Registered

2024-04-24

Start date

2016-01-01

Completion date

2021-12-31

Last updated

2024-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure With Reduced Ejection Fraction

Brief summary

Objective: To analyze factors associated with Thai heart failure with reduced ejection fraction patients who received sub-target doses of Angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor-neprilysin inhibitors (ARNIs), and angiotensin receptor blockers (ARBs). Methods: The retrospective cohort study was designed to collect data on Thai heart failure with reduced ejection fraction patients at Out-patient Clinic, Trat Hospital and Phrapokklao Hospital from January 2016 to December 2020. Thirteen factors were analyzed to determine their association with the sub-target group.

Interventions

DRUGRenin-Angiotensin System Inhibitor

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Patients who were first diagnosed be heart failure with left ventricular ejection fraction less than 40%. * Received one of ACEIs,ARBs,ARNI drugs.

Exclusion criteria

* Electronic medical records was not complete enough to analyse. * Patients who had history of heart transplantation or had heart transplantation plan in last 12 months.

Design outcomes

Primary

Measure	Time frame	Description
factors associated with sub - target dose of ACEIs,ARBs,ARNI	12 months	factors associated with Thai heart failure with reduced ejection fraction patients who received sub-target doses of Angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor-neprilysin inhibitors (ARNIs), and angiotensin receptor blockers (ARBs).

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026